Drug recall · April 19, 2017
BuPROPion Hydrochloride Extended-release Tablets recall
Why: Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged in a) 60-count bottles (NDC 59746-317-60) and b) 100-count bottles (NDC 59746-317-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.
- Lots / codes
Lot #s: a) BU34002A, BU34003A, Exp 11/16; b) BU34001A, Exp 10/16
- Quantity
- 19,682 bottles
- Company
- Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD
- Distribution
- Nationwide in the USA
- Initiated
- April 8, 2016 · Voluntary: Firm initiated
- Classified
- April 13, 2017
- Reported
- April 19, 2017
- Ended
- April 17, 2017
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupropion
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.